Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 3 Interventional Results available

Alternatives for Reducing Chorea in Huntington Disease

NCT01897896
Conditions
Chorea Associated With Huntington Disease
Interventions
SD-809
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 30 more
Conditions
Tourette Syndrome
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
27
States / cities
Dothan, Alabama • Sun City, Arizona • Rogers, Arkansas + 22 more
Completed Phase 3 Interventional Results available

Addressing Involuntary Movements in Tardive Dyskinesia

NCT02291861
Conditions
Tardive Dyskinesia
Interventions
SD-809, Placebo
Drug
Lead sponsor
Auspex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
53
States / cities
Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 43 more
Conditions
Tourette Syndrome
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
19
States / cities
Gainesville, Florida • Gulf Breeze, Florida • Miami, Florida + 14 more
Conditions
Tourette Syndrome
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
33
States / cities
Dothan, Alabama • Rogers, Arkansas • Anaheim, California + 27 more
Completed Phase 3 Interventional Results available

First Time Use of SD-809 in Huntington Disease

NCT01795859
Conditions
Chorea
Interventions
SD-809, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 33 more
Conditions
Cerebral Palsy, Dyskinetic
Interventions
TEV-50717
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • San Diego, California • Voorhees Township, New Jersey + 2 more
Conditions
Cerebral Palsy, Dyskinetic
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 19 more
Conditions
Dystonia, Primary
Interventions
Deutetrabenazine 6 MG
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania